Amylyx Pharmaceuticals has opened a U.S. Expanded Access Program that will allow up to 250 adults who have undergone Roux‑en‑Y gastric bypass surgery to receive its investigational drug avexitide outside of the ongoing Phase 3 LUCIDITY trial. The program is designed to give patients with post‑bariatric hypoglycemia (PBH) a therapeutic option when no approved treatments exist and when they cannot enroll in the pivotal study.
Avexitide is a first‑in‑class GLP‑1 receptor antagonist that reduces insulin secretion and stabilizes blood glucose. PBH affects roughly 8 % of bariatric patients and can cause severe, life‑threatening hypoglycemic episodes. By offering the drug through an EAP, Amylyx addresses a critical unmet medical need and positions avexitide as the first potential FDA‑approved therapy for PBH.
The Phase 3 LUCIDITY trial, which has already enrolled 78 participants, is expected to report topline data in the third quarter of 2026. A positive readout would support a commercial launch in 2027, and the EAP provides an early opportunity to collect safety and efficacy data in a real‑world setting that can inform regulatory submissions and payer discussions.
The EAP also serves a strategic purpose: it builds physician and patient familiarity with avexitide, generates real‑world evidence that can complement clinical trial data, and may improve recruitment for the ongoing study by demonstrating the company’s commitment to patient access.
Chief Medical Officer Camille L. Bedrosian said, "Listening to the PBH community is central to our work, and this dialogue directly informed our approach to the U.S. Expanded Access Program for avexitide. The experiences shared by those living with PBH underscore the profound unmet medical need they face every day. This program reflects our commitment to providing a potential option for eligible individuals as we continue to advance avexitide through clinical development."
Market data show that the announcement was well received, with the company’s shares rising 2.81 % on the day of the announcement. The move is viewed as a positive step toward commercial readiness and a potential catalyst for future regulatory and commercial milestones.
Amylyx’s cash position supports this initiative, with a runway projected through 2028. The company’s focus remains on avexitide, and the EAP underscores its strategy to bring the first approved therapy for PBH to market, potentially opening a new revenue stream and solidifying its position in a niche therapeutic area.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.